Press release
Protagen Protein Services and BioAnalytix Merge to Create Global Analytic Service Partner for Biopharmaceuticals
In working together with its pharmaceutical partners, the PPS and BioAnalytix teams generate best-in-class analytic data packages and provide scientific, technical and regulatory support to advance, de-risk and accelerate all stages of biopharmaceutical development at the highest of quality from clone through clinic.
Martin Blüggel, Founder and CEO of PPS, stated “Both companies have shared a similar vision, entrepreneurial agility and heritage of excellence in supporting leading pharmaceutical companies with high-end analytics and strategic solutions through development. We are very excited to serve our pharma partners more directly in the FDA and EMEA territories, and continue our expansion in capacities and capabilities, now including BioAnalytix’s innovative areas such as advanced HDX-MS and in-vivo CQA Mapping.”
Kirtland Poss, Founder and CEO of BioAnalytix added, “We are thrilled about the combination of both companies and their analytic offerings. The broader platforms will enable us to provide a significantly greater range of analytic data packages and regulatory support here in the US as we expand our capabilities in advancing, de-risking and accelerating all stages of biotherapeutic development with our pharma partners.”
By combining analytic platforms, programs and highly experienced analytic teams based both in US and in Europe, PPS and BioAnalytix will work directly and more broadly with leading biopharmaceutical companies in designing, generating and delivering integrated analytical data packages, and strategic support along the full development continuum, from developability and lead optimization, clone selection and process development, extended characterization and comparability, stability testing for control strategy design and CMC filings through commercialization and full GMP testing of commercial products.
About Protagen Protein Services
Protagen Protein Services GmbH (PPS) is a leading CRO and a recognized expert for GMP compliant protein analytical services. More than 20 years of market experience and the comprehensive spectrum of analytical methods ensure the highest quality for customers in the pharmaceutical, biotech and life science industry. PPS partners with customers in developing innovative biologics by providing full service analytical support, complete documentation and outstanding project management from clone to clinic. PPS supports biosimilar developers with a broad range of analytical methods and consulting in achieving and demonstrating biosimilarity.
About BioAnalytix
BioAnalytix, Inc. is a specialty analytic services company working with leading biotherapeutic companies in the development and application of advanced analytics and data analysis of complex biologics. Based in Cambridge, MA and becoming part of Protagen Protein Services GMBH, Germany in 2019, BioAnalytix’s programs are oriented around hybrid LC-MS, physical chemistry and data analysis platforms for precisely characterizing complex biotherapeutics from candidate selection through commercialization.
Corporate Contact
Martin Blüggel,
CEO Protagen Protein Services GmbH
Inselwiesenstrasse 10; 74067 Heilbronn, Germany and
Otto Hahn Str. 15; 44267 Dortmund, Germany
Phone +49 231 9742 6100
Email contact@protagenproteinservices.com
Media Contact
Tobias Timtner; Marketing Manager
Phone +49 7131 74504
Email marketing@protagenproteinservices.com
US Corporate Contacts
Kirtland Poss
CEO BioAnalytix Inc.
790 Memorial Drive
Cambridge, MA 02139, USA
Phone +1 857 829 3200
Email info@bioanalytixinc.com
Jules Abraham
JQA Partners, Inc.
Phone +1 917 885 7378
Email jabraham@jqapartners.com
US Media Contact
Mary Bowen; Director, Strategic & Digital Marketing
Phone +1 857 259 6706
Email mbowen@bioanalytixinc.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Protagen Protein Services and BioAnalytix Merge to Create Global Analytic Service Partner for Biopharmaceuticals here
News-ID: 1699326 • Views: …
More Releases from Protagen Protein Services GmbH
Analytical Toolbox for Cell and Gene Therapy development
Heilbronn/Dortmund Oct. 2020: Protagen Protein Services (PPS) guides you through the emerging field of gene therapy developments
Gene therapies plays an increasingly significant role in the future of medicine. Process development and quality testing are yet in the focus of the international authorities. Today, due to their specific characteristics as non self-replicative viral vectors, adeno-associated viruses (AAVs) are a safe approach for delivering the genes of interest.
Innovative companies face analytical challenges…
Business Continuity Plan - Message from Protagen Protein Services (PPS)
Following the recent COVID-19 outbreak, we at Protagen Protein Services (PPS) are preparing for all eventualities. Please be assured that PPS will continue to operate as normal providing you with all of the professional support and service you have to come to expect from us.
Given the gravity of the situation, and to protect our staff, clients, and communities from the spread of the virus, we have taken various measures within…
Stability Testing and Forced Degradation Stress Tests - Proactive Risk Managemen …
Whereas the durability of many consumables, have a strong tendency to decrease, stability is and remains a crucial factor for pharmaceuticals. That is why the identification and elimination of factors, which put long-term stability at risk, is central during development – and an important requirement concerning the product’s quality.
Stability studies are a fundamental part of the development of a biopharmaceutical. Proteins are sensitive to environmental factors: Changes in biopharmaceutical stability…
Protagen Protein Services (PPS) Invests in new PhysChem Analytical Capabilities …
Heilbronn/Dortmund 8. August: Amongst its structural attributes, a protein’s secondary structure features – such as alpha helices, beta sheets, and others conformations – are critical parameters that must be assessed diligently. FT-IR (Fourier-Transform Infrared) spectroscopy is highly sensitive to the secondary structure of proteins and has been widely used to investigate protein folding.
Comprehensive information on the numerous structural attributes of a protein therapeutic is vital for understanding its functionality, stability,…
More Releases for BioAnalytix
Mycotoxin Feed Testing Market Set for Strong Growth, Expected to Reach $2.11 bil …
Growing Application Driven by Climate Change Effects, Global Food Safety Concerns and Technological Advancements in Feed Solutions
What Is The Projected Market Size Of The Global Mycotoxin Feed Testing Global Market Report 2025 And Its Growth Rate?
• The mycotoxin feed testing market size is set to grow strongly and is projected to reach $1.55 billion in 2025 from $1.45 billion in 2024, at a CAGR of 6.4%.
• This surge in the…
Mycotoxin Feed Testing Market Growth Statistics, Regional Analysis, Top Players, …
"The Business Research Company recently released a comprehensive report on the Global Mycotoxin Feed Testing Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The mycotoxin feed testing…
Mycotoxin Feed Testing Market Set to Reach $1.96 Bn by 2033 - Market Share Analy …
The new report published by The Business Research Company, titled Mycotoxin Feed Testing Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the mycotoxin feed testing market size has grown strongly in recent years. It will grow from…
Clinical Trial Outsourcing Market to Reach Over $56 Billion by 2027- Arizton
According to Arizton's latest research report, clinical trials outsourcing market is expected to reach a revenue of over $56 billion, growing at a CAGR of over 6.5% during 2022-2027.The surge in the prevalence of various communicable and non-communicable diseases has propelled the demand for new therapies and drugs. Consequently, several pharmaceutical companies are conducting clinical trials for various indications. Most small and mid-sized biotechnology and pharmaceutical companies do not have…
Clinical Trials Outsourcing Market Overview, Cost Structure Analysis, Growth Opp …
The Clinical Trials Outsourcing report presents information related to restraints, key drivers, and opportunities, along with a detailed global market share analysis. The current market is quantitatively analyzed from 2022 to 2029 to highlight the global market growth scenario. The competitive landscape comprises key players, strategies, and new developments in the upcoming years.
Download FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=6185131
Key Companies & Market Share Insights
In this section, the readers will gain an…
The Clinical Trials Outsourcing Market to Grow at a CAGR of Around 7%.
AI in clinical trials is a game-changing technology that is primarily used by large CROs. During the COVID-19 pandemic period in recent years, AI applications were rapidly explored, accelerating clinical trials for a faster pandemic cure.
The following factors are likely to contribute to the growth of the clinical trials outsourcing market during the forecast period:
1. Rising Drug Discovery and Increasing Expenditure
2. Increasing Demand for Large Molecule Development, Rare Disease…
